Progenics Restructures To Become Leaner, Focus On Oncology
This article was originally published in The Pink Sheet Daily
Executive Summary
With an eye on efficiency, the biotech plans to shed its virology and infectious disease assets and transition to a pure-play oncology company.
You may also be interested in...
Baker Plans Business Development Focus For Progenics Pharma
The company founder stepped down as CEO to make room for a more business-minded leader.
Progenics Finds New Partner For Relistor In Salix
A casualty of the Pfizer/Wyeth merger, Relistor rights bring Progenics $60 million upfront plus up to $290 million in milestones plus royalties.
Mesoblast’s Late-Stage Pipeline Could Be Game Changing: Are Investors Paying Attention?
Mesenchymal cell specialist Mesoblast came back from a near-death experience in 2016 when Teva returned a key asset. But recent success in a Phase III trial in acute GVHD has brought it some attention. Now it needs to repeat the achievement in advanced heart failure and find a partner for its burgeoning pipeline.